

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-41. (Cancelled)

42. (New) A method of treating an autoimmune disease in a subject, the method comprising administering to the subject an effective amount of a composition comprising (a) an antibody or antigen-binding fragment thereof that binds to KIM-1, or (b) a polypeptide comprising a KIM-1 immunoglobulin domain.

43. (New) The method of claim 42, wherein the autoimmune disease is lupus.

44. (New) A method of treating an immunological disorder in a subject, the method comprising administering to the subject an effective amount of a composition comprising (a) an antibody or antigen-binding fragment thereof that binds to KIM-1, or (b) a polypeptide comprising a KIM-1 immunoglobulin domain, wherein the immunological disorder is myasthenia gravis, autoimmune hemolytic anemia, Chagas disease, Graves disease, idiopathic thrombocytopenia purpura, Wegener's granulomatosis, polyarteritis nodosa, rapidly progressive crescentic glomerulonephritis, or graft-versus-host disease.

45. (New) A method of treating an immunological disorder in a subject, the method comprising administering to the subject an effective amount of a composition comprising (a) an antibody or antigen-binding fragment thereof that binds to KIM-1, or (b) a polypeptide

comprising a KIM-1 immunoglobulin domain, wherein the immunological disorder is arthritis or an inflammatory bowel disease.

46. (New) The method of claim 42, wherein the composition comprises an antibody or antigen-binding fragment thereof that binds to KIM-1.

47. (New) The method of claim 46, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, monoclonal antibody, humanized antibody, fully human antibody, chimeric antibody, single-chain antibody, diabody, Fab fragment, Fab' fragment, F(ab')₂ fragment, Fv fragment, Fd fragment, dAb fragment, or complementarity determining region-containing fragment.

48. (New) The method of claim 42, wherein the composition comprises a polypeptide comprising the KIM-1 immunoglobulin domain.

49. (New) The method of claim 48, wherein the polypeptide further comprises a KIM-1 mucin domain.

50. (New) The method of claim 48, wherein the polypeptide further comprises a heterologous moiety.

51. (New) The method of claim 50, wherein the heterologous moiety is selected from the group consisting of a serum albumin moiety, a targeting moiety, a reporter moiety, and a purification-facilitating moiety.

52. (New) The method of claim 50, wherein the heterologous moiety is an immunoglobulin moiety.

53. (New) The method of claim 52, wherein the immunoglobulin moiety is an Fc moiety.

54. (New) The method of claim 50, wherein the polypeptide is conjugated to a polymer.